Abstract:Background and objectiveCognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson’s disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years).MethodsWe evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson’s Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein (APO) E status, β-glucocerebrosidase (GBA) mutation status, cerebrospinal fluid findings, and dopamine transporter imaging results. Using a diagnosis of CI (combined mild cognitive impairment and dementia) developed during the 5-year follow-up as outcome measures, we assessed the predictive values of baseline clinical variables and biomarkers. We also constructed a predictive model for the diagnosis of CI using logistic regression analysis.ResultsA total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and APOE status were associated with the development of CI. Predictive accuracy of CI using age alone improved by the addition of clinical variables and biomarkers (current diagnosis of hypertension, baseline MoCA scores, and MDS-UPDRS III scores, APOE status; AUC 0.80 [95% CI 0.74–0.86] vs. 0.71 [0.64–0.77], p = 0.008). Cognitive domains that had higher frequencies of impairment were found in verbal memory (12.6 vs. 16.8%) and attention/processing speed (12.7 vs. 16.9%), however, no significant difference in the prevalence of CI at annual follow-up was found during the 5-year follow-up in NDPD patients.ConclusionIn NDPD, the development of CI during the 5-year follow-up can be predicted with good accuracy using a model combining age, current diagnosis of hypertension, baseline MoCA scores, MDS-UPDRS III scores, and APOE status. Our study underscores the need for the earlier identification of CI in NDPD patients in our clinical practice.

Cognitive Deterioration Rates In Patients With Parkinson'S Disease From Northeastern China

A Risk Factor Analysis of Cognitive Impairment in Elderly Patients with Chronic Diseases in a Chinese Population

Characterizing Mild Cognitive Impairment in Prodromal Parkinson’s Disease: A Community‐based Study in China

Microstructural but not macrostructural cortical degeneration occurs in Parkinson’s disease with mild cognitive impairment

Assessment tools for cognitive performance in Parkinson's disease and its genetic contributors

Advanced brain aging in Parkinson’s disease with cognitive impairment

A Pilot Study Of Psychometric Properties Of The Beijing Version Of Montreal Cognitive Assessment In Patients With Idiopathic Parkinson'S Disease In China

Correlative Factors of Cognitive Dysfunction in PD Patients: a Cross-Sectional Study from Southwest China

[Study on the status of cognition among Parkinson's disease patients in Xi'an.].

Predictors of Cognitive Impairment in Newly Diagnosed Parkinson’s Disease with Normal Cognition at Baseline: A 5-Year Cohort Study

Cognitive Impairment is Common in Parkinson's Disease Without Dementia in the Early and Middle Stages in a Han Chinese Cohort.

Associations Between Cognitive Impairment and Motor Dysfunction in Parkinson's Disease

Cognitive Performance is Associated with Altered Cerebral Hemodynamics Assessed by Transcranial Ultrasound in Parkinson's Disease

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

Using the Montreal Cognitive Assessment Scale to screen for dementia in Chinese patients with Parkinson's Disease.

Cognitive Impairment in Patients with Parkinson's Disease: A 30-Month Follow-Up Study.

Capturing subjective cognitive decline with a new combined index in low education patients with Parkinson's disease

Cognitive function in PD patients without dementia

Mild cognitive impairment in patients with Parkinson´s disease and the analysis of associated factors

Validation of Revised Chinese Version of PD-CRS in Parkinson's Disease Patients

Cognitive Characteristics in Chinese Non-Demented PD Patients Based on Gender Difference